AR102204A1 - Compuestos derivados de amino-alquilbenzotiazepinas - Google Patents
Compuestos derivados de amino-alquilbenzotiazepinasInfo
- Publication number
- AR102204A1 AR102204A1 ARP150103242A ARP150103242A AR102204A1 AR 102204 A1 AR102204 A1 AR 102204A1 AR P150103242 A ARP150103242 A AR P150103242A AR P150103242 A ARP150103242 A AR P150103242A AR 102204 A1 AR102204 A1 AR 102204A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- carboxy
- carbamoyl
- sulfamoyloxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 20
- -1 hydroxy, carboxy Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/02—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/24—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a seven-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/06—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
La presente solicitud se refiere a un derivado de aminoalquilbenzotiazepina o a una sal aceptable para uso farmacéutico del mismo y a una composición farmacéutica para prevenir o tratar el estreñimiento que comprende el mismo como un principio activo. Reivindicación 1: Un compuesto representado por la fórmula (1) o una sal aceptable para uso farmacéutico del mismo, en la que R¹ es hidroxi, carboxi o hidroxisulfonil(alquilo C₁₋₄); R² y R³ son cada uno independientemente hidrógeno, alquilo C₁₋₄, hidroxi(alquilo C₁₋₄), carbamoil(alquilo C₁₋₄), carboxi, carboxi(alquilo C₁₋₄), (heteroarilo C₅₋₁₀)(alquilo C₁₋₄) o (arilo C₅₋₁₀)(alquilo C₁₋₄) o R² y R³, considerados juntos con el átomo de carbono respectivo al que están unidos, forman cicloalquileno C₃₋₇; R⁴ es hidrógeno carboxi(alquilo C₁₋₄); R⁵ es hidrógeno, halógeno, (alquil C₁₋₄)tio, (alquil C₁₋₄)amino o di(alquil C₁₋₄)amino; R⁶ y R⁷ son cada uno independientemente alquilo C₁₋₆; R⁸ y R⁹ son cada uno independientemente hidrógeno, hidroxi, alcoxi C₁₋₄, alquilo C₁₋₄, halógeno, nitro, ciano, amino, (alquil C₁₋₄)amino, di(alquil C₁₋₄)amino, acetamido, formilo, alcanoilo C₁₋₄, carboxi, carbamoílo, (alquil C₁₋₄)carbamoílo, di(alquil C₁₋₄)carbamoílo, carbamoíloxi, (alquil C₁₋₄)carbamoíloxi, di(alquil C₁₋₄)carbamoiloxi, (alquil C₁₋₄)sulfoniloxi, sulfamoiloxi, (alquil C₁₋₄)sulfamoiloxi o di(alquil C₁₋₄)sulfamoiloxi; Q es arilo C₅₋₁₀ o heteroarilo C₅₋₁₀; y n es un número entero de 0 a 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140141869 | 2014-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102204A1 true AR102204A1 (es) | 2017-02-08 |
Family
ID=56021635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103242A AR102204A1 (es) | 2014-10-20 | 2015-10-07 | Compuestos derivados de amino-alquilbenzotiazepinas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9890129B2 (es) |
| EP (1) | EP3210977B1 (es) |
| JP (1) | JP6386171B2 (es) |
| KR (1) | KR101674806B1 (es) |
| CN (1) | CN106573902B (es) |
| AR (1) | AR102204A1 (es) |
| AU (1) | AU2015336400B8 (es) |
| CA (1) | CA2951824C (es) |
| DK (1) | DK3210977T3 (es) |
| ES (1) | ES2729305T3 (es) |
| IL (1) | IL250668B (es) |
| MX (1) | MX2016016593A (es) |
| RU (1) | RU2679891C2 (es) |
| UY (1) | UY36342A (es) |
| WO (1) | WO2016064082A2 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2591188C2 (ru) | 2010-11-08 | 2016-07-10 | Альбирео Аб | Ингибиторы ibat для лечения заболеваний печени |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| KR101844184B1 (ko) | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11802115B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| AR120683A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| IL293379A (en) | 2019-12-04 | 2022-07-01 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202134223A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
| WO2021110885A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
| CN116583504A (zh) | 2020-12-04 | 2023-08-11 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CN114380681B (zh) * | 2022-01-27 | 2024-01-26 | 安徽皓元药业有限公司 | 一种2-(溴甲基)-2-丁基己酸的合成方法 |
| WO2023203248A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
| US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000772D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| EG26979A (en) * | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| US7312208B2 (en) * | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| WO2010062861A2 (en) * | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| WO2011081945A2 (en) | 2009-12-14 | 2011-07-07 | Cornell University | Activation and activators of sirt6 |
| JO3131B1 (ar) * | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| MX354242B (es) * | 2011-10-28 | 2018-02-20 | Lumena Pharmaceuticals Inc | Nhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas. |
-
2015
- 2015-05-19 KR KR1020150069949A patent/KR101674806B1/ko active IP Right Grant
- 2015-08-28 JP JP2017514289A patent/JP6386171B2/ja active Active
- 2015-08-28 EP EP15851901.7A patent/EP3210977B1/en active Active
- 2015-08-28 MX MX2016016593A patent/MX2016016593A/es active IP Right Grant
- 2015-08-28 US US15/506,634 patent/US9890129B2/en active Active
- 2015-08-28 AU AU2015336400A patent/AU2015336400B8/en active Active
- 2015-08-28 ES ES15851901T patent/ES2729305T3/es active Active
- 2015-08-28 DK DK15851901.7T patent/DK3210977T3/da active
- 2015-08-28 RU RU2017103920A patent/RU2679891C2/ru active
- 2015-08-28 CN CN201580044981.2A patent/CN106573902B/zh active Active
- 2015-08-28 WO PCT/KR2015/009044 patent/WO2016064082A2/ko active Application Filing
- 2015-08-28 CA CA2951824A patent/CA2951824C/en active Active
- 2015-10-02 UY UY0001036342A patent/UY36342A/es active IP Right Grant
- 2015-10-07 AR ARP150103242A patent/AR102204A1/es active IP Right Grant
-
2017
- 2017-02-19 IL IL250668A patent/IL250668B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20170283386A1 (en) | 2017-10-05 |
| RU2017103920A3 (es) | 2018-11-22 |
| CA2951824C (en) | 2019-01-08 |
| RU2679891C2 (ru) | 2019-02-14 |
| UY36342A (es) | 2016-06-01 |
| RU2017103920A (ru) | 2018-11-22 |
| IL250668B (en) | 2019-07-31 |
| US9890129B2 (en) | 2018-02-13 |
| KR20160047378A (ko) | 2016-05-02 |
| JP6386171B2 (ja) | 2018-09-05 |
| WO2016064082A3 (ko) | 2016-06-09 |
| JP2017527589A (ja) | 2017-09-21 |
| BR112016030599A8 (pt) | 2021-07-06 |
| AU2015336400A8 (en) | 2018-04-05 |
| IL250668A0 (en) | 2017-04-30 |
| EP3210977A4 (en) | 2018-04-11 |
| CN106573902A (zh) | 2017-04-19 |
| WO2016064082A2 (ko) | 2016-04-28 |
| CN106573902B (zh) | 2019-10-08 |
| EP3210977A2 (en) | 2017-08-30 |
| AU2015336400B8 (en) | 2018-04-05 |
| ES2729305T3 (es) | 2019-10-31 |
| CA2951824A1 (en) | 2016-04-28 |
| AU2015336400A1 (en) | 2016-12-22 |
| MX2016016593A (es) | 2017-04-27 |
| AU2015336400B2 (en) | 2017-12-07 |
| KR101674806B1 (ko) | 2016-11-10 |
| BR112016030599A2 (pt) | 2017-08-15 |
| EP3210977B1 (en) | 2019-03-20 |
| DK3210977T3 (da) | 2019-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
| CL2020003260A1 (es) | Compuestos de naftiridinona sustituidos útiles como activadores de células t | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
| UY39706A (es) | Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue | |
| BR112017010354B8 (pt) | Compostos de triazolopirimidina, seu uso, e composição farmacêutica | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR110405A1 (es) | Compuestos | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| CU24392B1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| TW201613864A (en) | Novel compounds | |
| AR091490A1 (es) | Antagonistas de iap | |
| PH12017501280A1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| AR101393A1 (es) | COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2 | |
| NZ721780A (en) | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | |
| MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
| AR097935A1 (es) | Derivados de piridazinonas útiles como herbicidas | |
| AR112283A1 (es) | Uso de derivados de aminoalquilbenzotiazepina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |